By Robert Cook-Deegan
Now that the Supreme Court has ruled that merely isolating a DNA sequence does not make it eligible to patent, the question arises, “What will happen to the crucially important data accumulated by an overly broad monopoly?”
The answer to this question has implications for people who may have an inherited risk for breast and ovarian cancer and to the scientists who hope to use that data for life-saving decisions about cancer surgery.
There has been such an avalanche of coverage of the Association for Molecular Pathology v. Myriad Genetics hearing at the Supreme Court on the 15th April, that I thought it might be useful to collate some of the best and the rest in one handy list. Please let me know if I’ve missed anything (the list I have at the moment is mostly from the American and European press so it would be particularly interesting to hear how this was covered elsewhere).